2025-12-162025-12-162022Urueña A, Micone P, Magneres MC, McGovern I, Mould-Quevedo J, Sarmento TTR, Giglio N. Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina. Vaccines. 2022; 10(10):1627. https://doi.org/10.3390/vaccines10101627https://doi.org/10.3390/vaccines10101627https://www.mdpi.com/2076-393X/10/10/1627http://rid.isalud.edu.ar/handle/1/3065Fil: Urueña A. Universidad Isalud. Centro de Estudios para la Prevención y Control de Enfermedades TransmisiblesBackground: Quadrivalent cell-based influenza vaccines (QIVc) avoid egg-adaptive mutations and can be more effective than traditional quadrivalent egg-based influenza vaccines (QIVe). This analysis compared the cost-effectiveness of QIVc and QIVe in Argentinian populations < 65 years old from the payer and societal perspectives. Methods: A static decision tree model compared the costs and health benefits of vaccination with QIVc vs. QIVe using a one-year time horizon. The relative vaccine effectiveness of QIVc vs. QIVe was assumed to be 8.1% for children and 11.4% for adults. An alternative high egg-adaptation scenario was also assessed. Model inputs were sourced from Argentina or the international literature. Deterministic and probabilistic sensitivity analyses were performed. Results: Compared to QIVe, QIVc would prevent 17,857 general practitioner visits, 2418 complications, 816 hospitalizations, and 12 deaths per year. From the payers’ perspective, the incremental cost-effectiveness ratio per quality-adjusted life years gained was USD12,214 in the base case and USD2311 in the high egg-adaptation scenario. QIVc was cost-saving from the societal perspective in both scenarios. Conclusions: QIVc in Argentina would be cost-effective relative to QIVe. The potential health benefits and savings would be even higher in high egg-adaptation seasons.enCC BY-NC-ND 4.5INFLUENZAVACUNASCOSTO EFECTIVIDADVACUNA BASADA EN CÉLULASArtículohttps://orcid.org/0000-0001-5108-2534